Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial
Year: 2025
Type: article
Language: en
Topic: Neuroendocrine Tumor Research Advances
Authors and affiliations:
raw_author_name: J. Capdevila
raw_affiliation_strings: Department of Medical Oncology, Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Neuroendocrine and Endocrine Tumor Translational Research Program (NET-VHIO), Vall Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
raw_author_name: S. Tafuto
raw_affiliation_strings: Sarcomas and Rare Tumors Unit, Istituto Nazionale Tumori IRCCS, Fondazione 'G.Pascale', Naples, Italy
raw_author_name: M. Krogh
raw_affiliation_strings: Medical Oncology Department, Odense University Hospital, Odense, Denmark
raw_author_name: A. Teulé
raw_affiliation_strings: Medical Oncology Department, Oncobell Program, IDIBELL, Institut Català d'Oncologia (ICO) Hospital Duran i Reynals, Barcelona, Spain; Clinical Sciences Department, Bellvitge Campus, University of Barcelona, CIBERONC, Barcelona, Spain
raw_author_name: R. Garcia-Carbonero
raw_affiliation_strings: Medical Oncology Department, Hospital Universitario 12 de Octubre, Imas12, UCM, Madrid, Spain
raw_author_name: H.-J. Klümpen
raw_affiliation_strings: Medical Oncology Department, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
raw_author_name: B. Cremer
raw_affiliation_strings: Medical Oncology Department, Universitätsklinikum Köln (AöR), Köln, Germany
raw_author_name: I. Sevilla
raw_affiliation_strings: Medical Oncology Department, Investigación Clínica y Traslacional en Cáncer, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria de Málaga, Málaga, Spain
raw_author_name: B. Eriksson
raw_affiliation_strings: Endocrine Oncology Department, Uppsala University Hospital, Uppsala, Sweden
raw_author_name: E. Tabaksblat
raw_affiliation_strings: Medical Oncology Department, Aarhus University Hospital, ENETS Center of Excellence, Aarhus, Denmark
raw_author_name: J.-P. Metges
raw_affiliation_strings: Medical Oncology Department, Brest Hôpital Augustin Morvan, Institut de Cancero-Hemato, Brest, France
raw_author_name: N.S. Reed
raw_affiliation_strings: Medical Oncology Department, Beatson Oncology Centre, Glasgow, UK
raw_author_name: J. Schrader
raw_affiliation_strings: Medical Oncology Department, Hamburg Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
raw_author_name: V. Navarro
raw_affiliation_strings: Clinical Research Unit, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Barcelona, Spain
raw_author_name: V. Valentí
raw_affiliation_strings: Medical Oncology Department, Oncobell Program, IDIBELL, Institut Català d'Oncologia (ICO) Hospital Duran i Reynals, Barcelona, Spain; Clinical Sciences Department, Bellvitge Campus, University of Barcelona, CIBERONC, Barcelona, Spain
raw_author_name: J. Hernando
raw_affiliation_strings: Department of Medical Oncology, Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Neuroendocrine and Endocrine Tumor Translational Research Program (NET-VHIO), Vall Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
raw_author_name: A.M. Colao
raw_affiliation_strings: Sarcomas and Rare Tumors Unit, Istituto Nazionale Tumori IRCCS, Fondazione 'G.Pascale', Naples, Italy
raw_author_name: L. Vestermark
raw_affiliation_strings: Medical Oncology Department, Odense University Hospital, Odense, Denmark
raw_author_name: C. Carnaghi
raw_affiliation_strings: Medical Oncology Department, Humanitas Cancer Center, Milano, Italy
raw_author_name: U.P. Knigge
raw_affiliation_strings: Department of Endocrinology, ENETS Center of Excellence, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
raw_author_name: P. Jimenez-Fonseca
raw_affiliation_strings: Medical Oncology Department, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain
raw_author_name: M. Benavent
raw_affiliation_strings: Medical Oncology Department, University Hospital Virgen del Rocío, Seville Institute of Biomedicine (IBIS), Seville, Spain
raw_author_name: J. de Vos-Geelen
raw_affiliation_strings: Medical Oncology Department, GROW - Research Institute for Oncology & Reproduction, Maastricht University Medical Centre, Maastricht, The Netherlands
raw_author_name: M. Venerito
raw_affiliation_strings: Department of Gastroenterology, Hepatology and Infectious Diseases, Universitätsklinikum Magdeburg A. ö. R, Magdeburg, Germany
raw_author_name: A. Von Werder
raw_affiliation_strings: Medical Oncology Department, München rechts der Isar II, Medizinische Klinik und Poliklinik, München, Germany
raw_author_name: H. Jann
raw_affiliation_strings: Medical Oncology Department, Berlin Charité Universitätsmedizin, Berlin, Germany
raw_author_name: A. Rinke
raw_affiliation_strings: Department of Gastroenterology, Marburg Universitätsklinikum Giessen und Marburg, Marburg, Germany; Philipps University Marburg, Marburg, Germany
raw_author_name: D. Smith
raw_affiliation_strings: Medical Oncology Department, Bordeaux University Hospital-CHU Bordeaux, Hôpital Saint-André, Bordeaux, France
raw_author_name: D. Hörsch
raw_affiliation_strings: Medical Oncology Department, Bad Berka ChA Klinik für Innere Medizin, Bad Berka, Germany
raw_author_name: N. Starling
raw_affiliation_strings: Medical Oncology Department, The Royal Marsden NHS Foundation Trust, Sutton, UK
raw_author_name: P. Ruszniewski
raw_affiliation_strings: Medical Oncology Department, Université Paris Cité, Beaujon Hospital, APHP, Clichy, France
raw_author_name: E. Baudin
raw_affiliation_strings: Medical Oncology Department, Villejuif Institut Gustave-Roussy, Paris, France
raw_author_name: F.-X. Caroli-Bosc
raw_affiliation_strings: Medical Oncology Department, Unité Transversale de Thérapeutiques Innovantes en Oncologie Médicale (UTTIOM), Centre Hospitalier Universitaire (CHU) Angers, Angers, France
raw_author_name: J.L. Manzano
raw_affiliation_strings: Medical Oncology Department, Institut Català d'Oncologia (ICO), ICO-Badalona, H. Germans Trias i Pujol, Badalona, Barcelona, Spain
raw_author_name: M. Martín
raw_affiliation_strings: Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
raw_author_name: A. Scarpa
raw_affiliation_strings: ARC-Net Research Center, University and Hospital Trust of Verona, Verona, Italy; Department of Diagnostics and Public Health, Section of Pathology, and Department of Engineering for Innovative Medicine, University of Verona, Verona, Italy
raw_author_name: R.T. Lawlor
raw_affiliation_strings: ARC-Net Research Center, University and Hospital Trust of Verona, Verona, Italy; Department of Diagnostics and Public Health, Section of Pathology, and Department of Engineering for Innovative Medicine, University of Verona, Verona, Italy
raw_author_name: C. Ragulan
raw_affiliation_strings: Division of Molecular Pathology, Institute of Cancer Research, London, UK
raw_author_name: H. Ps
raw_affiliation_strings: Division of Molecular Pathology, Institute of Cancer Research, London, UK
raw_author_name: A. Sadanandam
raw_affiliation_strings: Division of Molecular Pathology, Institute of Cancer Research, London, UK
raw_author_name: A. Carmona-Bayonas
raw_affiliation_strings: Medical Oncology Department, Hospital General Universitario Morales Meseguer, UMU, IMIB, Murcia, Spain
raw_author_name: R. Salazar
raw_affiliation_strings: Medical Oncology Department, Oncobell Program, IDIBELL, Institut Català d'Oncologia (ICO) Hospital Duran i Reynals, Barcelona, Spain; Clinical Sciences Department, Bellvitge Campus, University of Barcelona, CIBERONC, Barcelona, Spain. Electronic address: ramonsalazar@iconcologia.net